EKSO BIONICS (EKSO) Price & Analysis

Compare

638 Followers

EKSO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.73 - $19.20

Previous CloseN/A

Volume1.71M

Average Volume (3M)100.22K

Market Cap

$9.79M

Enterprise Value$7.32M

Total Cash (Recent Filing)$5.24M

Total Debt (Recent Filing)$5.39M

Price to Earnings (P/E)―

Beta1.71

Next Earnings

Oct 30, 2025

EPS Estimate

-0.97

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.24

Shares Outstanding2,611,788

10 Day Avg. Volume37,687

30 Day Avg. Volume100,224

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.75

Enterprise Value/Revenue0.50

Enterprise Value/Gross Profit0.97

Enterprise Value/Ebitda-0.61

Forecast

1Y Price Target

$5.83

Price Target Upside55.47% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Market ExpansionCollaborating with PRIA Healthcare to navigate Medicare payments could lead to a rapid increase in the volume of future claims, generating meaningful revenue from Indego Personal.

Product LaunchThe continued progress on the launch of the Indego Personal product could provide a hedge to some of the macro challenges that the company is currently facing.

Strategic PartnershipsA new collaboration with Bionic Prosthetics & Orthotics Group to distribute Indego Personal within the orthotics and prosthetics industry.

Bears Say

Enterprise RevenueSofter enterprise revenue due to customer budget cuts.

Order DelaysUnexpected order delays contributed to enterprise revenue softness during 2Q25.

Revenue PerformanceEkso reported 2Q25 total revenues of $2.1M, a -58% YoY decline from $5.0M in 2Q24 and significantly below the consensus expectation of $4.3M.

EKSO BIONICS News

Ekso Bionics’ Exoskeleton Study: A Potential Game-Changer for Health and Finance

Ekso Bionics Holding (($EKSO)) announced an update on their ongoing clinical study. Ekso Bionics Holding is conducting a...

25d ago

EKSO

Ekso Bionics: Overcoming Order Delays with Strategic Partnerships and Strong Financial Position

EKSO BIONICS, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from...

26d ago

EKSO

Ekso Bionics’ Earnings Call: Mixed Results with Promising Initiatives

Ekso Bionics Holding (($EKSO)) has held its Q2 earnings call. Read on for the main highlights of the...

1M ago

EKSO

Ekso Bionics price target lowered to $9.50 from $15 at Lake Street

Lake Street lowered the firm’s price target on Ekso Bionics (EKSO) to $9.50 from $15 and keeps a...

1M ago

EKSO

Ekso Bionics Reports Q2 2025 Financial Results

Ekso Bionics Holding ( ($EKSO) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

EKSO

Ekso Bionics reports Q2 EPS ($1.24) vs. ($1.99) last year

Reports Q2 revenue $2.06M vs. $4.95M last year. “While there was abnormal weakness in the second quarter, in...

1M ago

EKSO

EKSO Upcoming Earnings Report: What to Expect?

Ekso Bionics Holding (EKSO) is scheduled to report 2nd quarter earnings on 07/28/2025, after the market closes. Regarding...

1M ago

EKSO

Ekso Bionics announces launch of eksoUniversity platform

Ekso Bionics (EKSO) announced the launch of eksoUniversity, a new platform providing continuing education courses to physical therapists...

2M ago

EKSO

Ekso Bionics demonstrates initial PoC in AI-enabled capability integration

Ekso Bionics (EKSO) has demonstrated initial proof-of-concept in integrating artificial intelligence-enabled capabilities across its portfolio of Enterprise Health...

3M ago

EKSO

Upcoming Stock Splits This Week (June 2 to June 6) – Stay Invested

These are the upcoming stock splits for the week of June 2 to June 6, based on TipRanks’ Stock...

3M ago

AGMH

APDN

Ekso Bionics trading halted, news pending

19:50 EDT Ekso Bionics (EKSO) trading halted, news pending Published first on TheFly – the ultimate source for...

3M ago

EKSO

Ekso Bionics Announces Reverse Stock Split Approval

EKSO BIONICS ( ($EKSO) ) just unveiled an announcement. On May 16, 2025, Ekso Bionics’ stockholders approved a...

3M ago

EKSO

Ekso Bionics Approves Reverse Stock Split Plan

An announcement from EKSO BIONICS ( ($EKSO) ) is now available. On May 16, 2025, Ekso Bionics held...

3M ago

EKSO

Ekso Bionics to effect 1-for-15 reverse stock split

Ekso Bionics announced that it will effect a reverse stock split of shares of its common stock at...

4M ago

EKSO

EKSO FAQ

What was Ekso Bionics Holding’s price range in the past 12 months?

Ekso Bionics Holding lowest stock price was $2.73 and its highest was $19.20 in the past 12 months.

What is Ekso Bionics Holding’s market cap?

Ekso Bionics Holding’s market cap is $9.79M.

When is Ekso Bionics Holding’s upcoming earnings report date?

Ekso Bionics Holding’s upcoming earnings report date is Oct 30, 2025 which is in 58 days.

How were Ekso Bionics Holding’s earnings last quarter?

Ekso Bionics Holding released its earnings results on Jul 28, 2025. The company reported -$1.24 earnings per share for the quarter, beating the consensus estimate of -$1.35 by $0.11.

Is Ekso Bionics Holding overvalued?

According to Wall Street analysts Ekso Bionics Holding’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ekso Bionics Holding pay dividends?

Ekso Bionics Holding does not currently pay dividends.

What is Ekso Bionics Holding’s EPS estimate?

Ekso Bionics Holding’s EPS estimate is -0.97.

How many shares outstanding does Ekso Bionics Holding have?

Ekso Bionics Holding has 2,611,788 shares outstanding.

What happened to Ekso Bionics Holding’s price movement after its last earnings report?

Ekso Bionics Holding reported an EPS of -$1.24 in its last earnings report, beating expectations of -$1.35. Following the earnings report the stock price went down -27.373%.

Which hedge fund is a major shareholder of Ekso Bionics Holding?

Currently, no hedge funds are holding shares in EKSO

Company Description

Ekso Bionics Holding

EKSO BIONICS (EKSO) is a technology company focused on developing advanced robotic exoskeletons designed to assist individuals with mobility impairments. Operating primarily in the healthcare sector, EKSO creates innovative solutions for rehabilitation and physical therapy, enabling users to regain movement and independence. Their flagship products include the EksoGT, an exoskeleton designed for gait training in rehabilitation settings, and the EksoVest, a wearable exoskeleton that helps reduce fatigue and strain for workers in industrial settings.

EKSO BIONICS (EKSO) Earnings & Revenues

Historic Earnings Reports

EKSO Company Deck

EKSO Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Negative

The earnings call highlighted significant challenges, including a major decline in revenue and gross margin, alongside an increased net loss. Despite these challenges, there were positive developments in the personal health segment, strategic partnerships, and AI initiatives. However, the financial setbacks appear to overshadow the positive developments.View all EKSO earnings summaries

EKSO Stock 12 Month Forecast

Average Price Target

$5.83

▲(55.47% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","6":"$6","10":"$10","14":"$14","18":"$18"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6,10,14,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.49,3.9523076923076923,4.414615384615384,4.876923076923077,5.3392307692307694,5.8015384615384615,6.2638461538461545,6.726153846153847,7.188461538461539,7.650769230769231,8.113076923076923,8.575384615384616,9.037692307692307,{"y":9.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.49,3.6700000000000004,3.85,4.03,4.21,4.390000000000001,4.57,4.75,4.93,5.11,5.29,5.470000000000001,5.65,{"y":5.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.49,3.5292307692307694,3.5684615384615386,3.6076923076923078,3.646923076923077,3.686153846153846,3.7253846153846153,3.764615384615385,3.803846153846154,3.8430769230769233,3.8823076923076925,3.9215384615384616,3.960769230769231,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.25,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.6,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.75,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.31,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.35,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.87,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.39,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >